Skip to main content
Fig. 5 | BMC Medicine

Fig. 5

From: Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical outcomes

Fig. 5

Drug-resistant mechanism analysis using patients with paired baseline and PD samples (n = 95). A The comparison of EGFR mutation status between paired baseline and PD samples. Each column represented a sample derived from a patient, and the two oncoprint plots (i.e., baseline vs PD to first-line TKIs) used the same order to arrange the paired patient samples. The frequency of mutated genes (B) or altered signaling pathways (C) between the baseline samples and PD samples. D The status of aberrant signaling pathways between the baseline and the paired PD samples, stratified by different compound EGFR mutation subtypes. BL, baseline; PD, progressive disease

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us